المؤلفون: Pogorzelski, Michael, Hilser, Thomas, Ting, Saskia C., Kansy, Benjamin, Gauler, Thomas C., Stuschke, Martin, Schmid, Kurt W., Lang, Stephan, Grünwald, Viktor, Schuler, Martin, Kasper, Stefan

مصطلحات موضوعية: ddc:610, Medizinische Fakultät » Universitätsklinikum Essen » Innere Klinik (Tumorforschung), Medizinische Fakultät » Universitätsklinikum Essen » Institut für Pathologie und Neuropathologie, Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Hals-Nasen-Ohrenheilkunde, Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Strahlentherapie, Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Urologie, cetuximab, head and neck cancer, prognostic markers, predictive markers, systemic treatment, resistance mechanism, prognostic score

الوصف: Cetuximab-based chemoimmunotherapy has been the standard of care for recurrent or metastatic squamous cell carcinoma of the head and neck (r/m SCCHN) for more than a decade. To date, no predictive or prognostic biomarkers have been established to further guide the systemic treatment with cetuximab-based chemoimmunotherapy in r/m SCCHN. Against this background, we retrospectively analyzed clinical and blood-based parameters from 218 r/m SCCHN patients treated with chemoimmunotherapy including cetuximab. Multivariate Cox-regression models were used to assess their prognostic or predictive value. Eastern Co-operative Oncology Group (ECOG) performance status (≥2), older age (≥61.8 years), anemia (hemoglobin <11.80), and increased neutrophil-to-lymphocyte ratio (NLR ≥5.73) were independently and strongly associated with inferior overall survival (OS). To group patients according to risk profiles we established a prognostic clinical score (PCS) that can easily be used in clinical practice. The PCS stratified the cohort into low, intermediate, poor or very poor risk subgroups with median OS times of 23.4, 12.1, 7.5, and 4.0 months, respectively. Patients with low risk PCS had a prolonged progression-free survival (PFS) and increased overall response rate (ORR) under first-line cetuximab-based therapy. Interestingly, only patients with low and intermediate risk benefitted from the more intensive first-line cisplatin/cetuximab combination compared to carboplatin/cetuximab therapy, whereas the intensity of first-line treatment had no impact in the poor and very poor risk subgroups. Following external validation, particularly in the context of newly established first-line options, the PCS may guide clinical decision making and serve for stratification of patients with r/m SCCHN in future clinical trials.

العلاقة: https://doi.org/10.3389/fonc.2021.635096Test; https://nbn-resolving.org/urn:nbn:de:hbz:464-20210722-154416-6Test; https://duepublico2.uni-due.de/receive/duepublico_mods_00074588Test; https://duepublico2.uni-due.de/servlets/MCRFileNodeServlet/duepublico_derivate_00074388/fonc-11-635096_Pogorzelski_et_al.pdfTest

الإتاحة: https://doi.org/10.3389/fonc.2021.635096Test
https://nbn-resolving.org/urn:nbn:de:hbz:464-20210722-154416-6Test
https://duepublico2.uni-due.de/receive/duepublico_mods_00074588Test
https://duepublico2.uni-due.de/servlets/MCRFileNodeServlet/duepublico_derivate_00074388/fonc-11-635096_Pogorzelski_et_al.pdfTest

المؤلفون: Goerling, Ute, Gauler, Thomas, Dietz, Andreas, Grünwald, Viktor, Knipping, Stephan, Guntinas-Lichius, Orlando, Frickhofen, Norbert, Lindeman, Hans-Walter, Fietkau, Rainer, Haxel, Boris, Große-Thie, Christina, Maschmeyer, Georg, Zipfel, Matthias, Martus, Peter, Knoedler, Maren, Keilholz, Ulrich, Klinghammer, Konrad

مصطلحات موضوعية: Therapy intensification, Docetaxel, Head and neck cancer, Quality of life, Recurrent and metastatic, ddc:610

الوصف: Introduction: CeFCiD was a multicenter phase II study comparing the efficacy of cetuximab (C), 5-flourouracil, and cisplatin with the same regimen adding docetaxel (D) in recurrent/metastatic head and neck cancer. The primary analysis trial did not demonstrate survival benefit from therapy intensification in first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The current analysis of the trial assessed the impact of treatment on quality of life (QoL). Methods: The European Organization for Research and Treatment of Cancer Quality of life Questionnaire QLQ-C30 and the tumor-specific module for head and neck cancer (QLQ-H&N35) were used to assess QoL at baseline (visit 1), after 2 (visit 3), 4 (visit 5), and 6 (visit 7) cycles of chemotherapy. Results: Of 180 patients included in this study, 86 patients (47.8%) completed the questionnaires at baseline. Considering selected scores over treatment time, there was no difference in global QoL, dyspnea, swallowing, and speech between the treatment arms in the course. For fatigue, a significant increase from baseline to visit 3 (p = 0.02), visit 5 (p = 0.002), and to visit 7 (p = 0.003) was observed for patients receiving D, cisplatin or carboplatin (P), 5-fluorouracil (F), and C. At the end of chemotherapy, the manifestation of fatigue was similar compared in the 2 treatment arms. Discussion/Conclusion: Therapy intensification not adversely affects selected scores of QoL of patients with recurrent and/or metastatic SCCHN. Nevertheless, fatigue seems to be pronounced in patients treated with D.

وصف الملف: application/pdf

العلاقة: https://refubium.fu-berlin.de/handle/fub188/39801Test; http://dx.doi.org/10.17169/refubium-39520Test

الإتاحة: https://doi.org/10.17169/refubium-39520Test
https://doi.org/10.1159/000521415Test
https://refubium.fu-berlin.de/handle/fub188/39801Test

المؤلفون: Eggers, Hendrik, Häbel, Lea, Ganser, Arnold, Grünwald, Viktor, Merten, Roland, Warnecke, Athanasia, Durisin, Martin, Ivanyi, Philipp

المصدر: Cancer Investigation; Jan2023, Vol. 41 Issue 1, p93-100, 8p

مصطلحات موضوعية: LUNG cancer prognosis, THERAPEUTIC use of monoclonal antibodies, LUNG cancer, CONFIDENCE intervals, EPIDERMAL growth factor receptors, METASTASIS, CANCER relapse, TREATMENT effectiveness, QUALITY assurance, DESCRIPTIVE statistics, PALLIATIVE treatment, OVERALL survival, PROPORTIONAL hazards models

مصطلحات جغرافية: GERMANY

مستخلص: Patients with R/M HNSCC treated with palliative first-line therapy at Hannover Medical School between October 2005 and December 2016 have been included to show changes in survival following broad utilization of cetuximab. Treatment periods were defined from 10/2005 to 12/2008 (Period A) and 01/2009 to 12/2016. Overall survival did not improve over time. However, in subgroup analysis cetuximab utilized at any time vs. never showed a significant improve of overall survival (11.3 vs. 6.3 months, HR: 0.55, 95%-CI: 0.4–0.8, p = 0.04). Therefore, this study supports the application of cetuximab in this real-world population. [ABSTRACT FROM AUTHOR]

: Copyright of Cancer Investigation is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Goerling, Ute, Gauler, Thomas, Dietz, Andreas, Grünwald, Viktor, Knipping, Stephan, Guntinas-Lichius, Orlando, Frickhofen, Norbert, Lindeman, Hans-Walter, Fietkau, Rainer, Haxel, Boris, Große-Thie, Christina, Maschmeyer, Georg, Zipfel, Matthias, Martus, Peter, Knoedler, Maren, Keilholz, Ulrich, Klinghammer, Konrad

المصدر: Oncology Research & Treatment; Jun2022, Vol. 45 Issue 6, p319-325, 7p

مصطلحات موضوعية: HEAD & neck cancer, CETUXIMAB, CISPLATIN, DOCETAXEL, FLUOROURACIL

مستخلص: Introduction: CeFCiD was a multicenter phase II study comparing the efficacy of cetuximab (C), 5-flourouracil, and cisplatin with the same regimen adding docetaxel (D) in recurrent/metastatic head and neck cancer. The primary analysis trial did not demonstrate survival benefit from therapy intensification in first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The current analysis of the trial assessed the impact of treatment on quality of life (QoL). Methods: The European Organization for Research and Treatment of Cancer Quality of life Questionnaire QLQ-C30 and the tumor-specific module for head and neck cancer (QLQ-H&N35) were used to assess QoL at baseline (visit 1), after 2 (visit 3), 4 (visit 5), and 6 (visit 7) cycles of chemotherapy. Results: Of 180 patients included in this study, 86 patients (47.8%) completed the questionnaires at baseline. Considering selected scores over treatment time, there was no difference in global QoL, dyspnea, swallowing, and speech between the treatment arms in the course. For fatigue, a significant increase from baseline to visit 3 (p = 0.02), visit 5 (p = 0.002), and to visit 7 (p = 0.003) was observed for patients receiving D, cisplatin or carboplatin (P), 5-fluorouracil (F), and C. At the end of chemotherapy, the manifestation of fatigue was similar compared in the 2 treatment arms. Discussion/Conclusion: Therapy intensification not adversely affects selected scores of QoL of patients with recurrent and/or metastatic SCCHN. Nevertheless, fatigue seems to be pronounced in patients treated with D. [ABSTRACT FROM AUTHOR]

: Copyright of Oncology Research & Treatment is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Grünwald, Viktor^1,2 (AUTHOR) gruenwald.viktor@mh-hannover.de, Chirovsky, Diana^1,3 (AUTHOR) diana.chirovsky@merck.com, Cheung, Winson Y.^4,5 (AUTHOR) winson.cheung@ahs.ca, Bertolini, Federica⁶ (AUTHOR) bertolini.federica@policlinico.mo.it, Ahn, Myung-Ju⁷ (AUTHOR) silkahn@skku.edu, Yang, Muh-Hwa⁸ (AUTHOR) mhyang2@vghtpe.gov.tw, Castro, Gilberto⁹ (AUTHOR) gilberto.cjunior@hsl.org.br, Berrocal, Alfonso¹⁰ (AUTHOR) berrocal_alf@gva.es, Sjoquist, Katrin^11,12 (AUTHOR) katrin.sjoquist@ctc.usyd.edu.au, Kuyas, Hélène¹³ (AUTHOR) helene.kuyas@kantarhealth.com, Auclair, Valérie¹³ (AUTHOR) valerie.auclair@kantarhealth.com, Guillaume, Xavier¹³ (AUTHOR) xavier.guillaume@kantarhealth.com, Joo, Seongjung³ (AUTHOR) seongjung.joo@merck.com, Shah, Roshani³ (AUTHOR) roshani1130@gmail.com, Harrington, Kevin¹⁴ (AUTHOR) Kevin.Harrington@icr.ac.uk, GLANCE H&N STUDY Investigators (CORPORATE AUTHOR)

المصدر: Oral Oncology. Mar2020, Vol. 102, pN.PAG-N.PAG. 1p.

مصطلحات موضوعية: *SQUAMOUS cell carcinoma, *TREATMENT effectiveness, *HEAD & neck cancer, *OROPHARYNGEAL cancer, *THERAPEUTIC use of antineoplastic agents, *HEAD tumors, *PLATINUM compounds, *RESEARCH, *CONFIDENCE intervals, *RESEARCH methodology, *CANCER relapse, *RETROSPECTIVE studies, *MEDICAL cooperation, *EVALUATION research, *FLUOROURACIL, *METHOTREXATE, *HYDROCARBONS, *COMPARATIVE studies, *KAPLAN-Meier estimator, *NECK tumors

مصطلحات جغرافية: EUROPE, TAIWAN, SOUTH Korea, CANADA, BRAZIL, AUSTRALIA

مستخلص: Objectives: Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utilization and survival outcomes for R/M HNSCC in the real-world setting.Materials and Methods: A multi-site retrospective chart review was conducted in Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), and Latin/North America (Brazil and Canada) to identify patients who initiated first-line systemic therapy for R/M HNSCC between January 2011 and December 2013. Patients were followed through December 2015 to collect clinical characteristics, treatment and survival data.Results: Among 733 R/M HNSCC patients across 71 sites, median age was 60 years (inter-quartile range 54-67), 84% male, and 70% Eastern Cooperative Oncology Group performance status 0-1; 32% had oral cavity and 30% oropharyngeal cancers. The most common first-line regimen across all countries consisted of platinum-based combinations (73%), including platinum + 5-fluorouracil (5-FU) (26%), cetuximab + platinum ± 5-FU (22%), or taxane + platinum ± 5-FU (16%). However, use of different platinum-based combinations varied substantially; administration of cetuximab + platinum ± 5-FU was frequent in Italy (81%), Germany (46%) and Spain (38%), whereas use in other countries was limited. Median follow-up was 22.6 months (95% confidence interval [CI]: 21.5-24.6 months). Median real-world overall survival was only 8.0 months (95% CI: 7.0-8.0), with one-year survival reaching only 30.9% (95% CI: 27.5-34.3).Conclusion: Systemic therapies used in clinical practice for patients with R/M HNSCC vary substantially across countries. Prognosis remains poor in this patient population, highlighting the need for newer, more efficacious treatments. [ABSTRACT FROM AUTHOR]